Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Proteomics Biomarker Development Laboratory

Proteomics Biomarker Development Laboratory

53

No lead investigator defined.

No coordinating investigator defined.

No involved investigator sites defined.

Case/control
UNKNOWN

The Biomarker Development Laboratory is focused on the application of a proteomic approach for the development of cancer biomarkers. The laboratory will apply technologies for protein analysis to the detection and identification of proteins secreted by tumor cells and protein antigens that induce a humoral response in tumors. The initial targeted tumor types for the identification of potential biomarker proteins are: Colon, esophagus, ovary, lung, breast and liver. The proposed studies will make heavy utilization of two-dimensional (2-D) protein analysis, of protein identification technologies and of database capabilities that have been developed by the applicant group. The objectives of this research are to 1. Identify tumor antigens that induce a humoral response; 2. Identify tumor secreted proteins and developa database; 3. Preliminarily validate the potential utilityof markers for early cancer detection. Sixty ml of bloodwill be obtained from healthy normals, and from small cell lung cancer, hepatoma, esophageal, and breast cancerpatients, and from ovarian, colon, and non-small cell lungcancer patients prior to surgical resection and six toten weeks after resection. Demographic data, sera and DNA will be used in 2-D protein analysis to identify newor altered proteins. The initial validation will be the assay of the presence or absence of a given protein in alarge sample cohort from the samples collected from thesepatients. There is no specified age range, although the diseases under study do not occur in children. No subjectswill be excluded on the basis of race or gender. Womenof child bearing age will be studied. Linkable demographicdata will be held separately from the bar-coded serum orDNA samples. Serum and DNA sample will be identifiableonly by subject identification number. Full written informed consent will be obtained from patients.

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 12/02/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.